Neurology

 
Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents
February 27, 2025

While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.

Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
February 26, 2025

Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.

Symbravo for Migraine Demonstrates Efficacy Superior to Prior CGRP Inhibitor Treatment in Phase 3 Trial
February 25, 2025

Symbravo, compared with previous CGRP inhibitor therapy, achieved superior response across efficacy measures including pain freedom and improvements in QoL.

Sinaptica Announces Enrollment for Phase 2 Clinical Trial in Early Alzheimer Disease of Dual Neuromodulation System
February 24, 2025

The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.

Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose
February 12, 2025

Your daily dose of the clinical news you may have missed.

Overlap in Pathophysiology Suggests New Approaches to Acute Pain May Transfer to Relief from Chronic Pain: A Closer Look
February 12, 2025

Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.

New Biomarkers Identified for Early Detection of Alzheimer Disease
February 11, 2025

Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.

Heart Disease Remains Leading Cause of Death in US: Daily Dose
February 11, 2025

Your daily dose of the clinical news you may have missed.

Suzetrigine (Journvax) Fits Neatly in a Multimodal Strategy to Manage Acute Pain, According to Edward Mariano, MD, MAS
February 11, 2025

Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.

Headaches and Suicide
February 10, 2025

The risk of a suicide attempt was 2 times greater among those with headache, across types including tension type headache, migraine, trigeminal autonomic cephalalgia, and posttraumatic headache.